| abstract |
Dosage form of bisphosphonate, comprising a bisphosphonate selected from risedronate, alendronate, pamidronate, tiludronate, cimadronate, ibandronate, clodronate, zoledronate, preferably 0.5 to 75% risedronate and its salts, esters, hydrates, polymorphs, hemihydrates, solvates and combinations thereof, 10 to 1000 mg of a chelating agent, selected from ethylenediaminetetraacetic acids (EDTA), citric, malic, tartaric, aspartic, glutamic, and lysine and sodium hexametaphosphate, its salts and combinations, and a delayed release mechanism for bisphosphonate and the chelator in the lower gastrointestinal tract, selected from pH activated systems, by bacterial enzymes, time dependent and mixtures thereof. Oral dosage form with enteric coating and case that facilitates its use for the treatment of disorders of calcium and phosphate metabolism, applicable once a day, week or month, which mitigates gastrointestinal irritation and interaction with drinks or food. |